Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Chari, Ajai; Suvannasankha, Attaya; W. Fay, Joseph; Arnulf, Bertrand; L. Kaufman, Jonathan; J. Ifthikharuddin, Jainulabdeen; M. Weiss, Brendan; Krishnan, Amrita; Lentzsch, Suzanne; L. Comenzo, Raymond; Wang, Jianping; Nottage, Kerri; Chiu, Christopher; Z. Khokhar, Nushmia; Ahmadi, Tahamtan; Lonial, Sagar

doi:10.1182/blood-2017-05-785246

Public

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Published in Blood • Jun 22, 2017

Authors:

Ajai Chari

Attaya Suvannasankha

Joseph W. Fay

Abstract

Among the 62 responders, median duration of response was not estimable (NE; 95% confidence interval [CI], 13.6-NE). At a median follow-up of 13.1 months, the median progression-free survival was 8.8 (95% CI, 4.6-15.4) months and median overall survival was 17.5 (95% CI, 13.3-NE) months. The estimate...

Subject

Daratumumab

Pomalidomide

Dexamethasone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!